VEEVVEEV
US • —
$177.47
P/E
31.40
PEG
1.58
FCF Yield
—
Rev Growth YoY
+16.2% YoY
Gross Margin
75.0%
Health Score
8/10
D/E Ratio
—
Confidence
LOW
Business Snapshot
Veeva Systems provides cloud-based software solutions for the global life sciences industry, with its primary revenue generated from its Vault applications suite and its commercial CRM platform. The company operates as the dominant market leader in cloud software tailored specifically for pharmaceutical, biotech, and medical device companies, benefiting from a regulatory and data-integrity moat that makes its solutions difficult to replace. With a market capitalisation that typically positions it as a large-cap growth technology company, its TTM revenue is substantial though not explicitly stated in the available data. The defining characteristic distinguishing Veeva is its deep vertical focus on life sciences, creating high switching costs and a stickier customer base compared to horizontal enterprise software providers.
Financial Health
Gross margin stands at a very strong 75.0%, and the net margin is an impressive 28.4%, indicating highly profitable operations with significant pricing power and operational leverage. The balance sheet is notably conservative with a debt/equity ratio of 0.0x and a current ratio of 4.89x, meaning the company holds no debt and has ample short-term liquidity to cover any current obligations...
Risk Assessment
- VALUATION — P/E of 31.4x trades at a notable 43% premium to the sector average of 22x, pricing in a high degree of future perfection.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- DCF / CASH FLOW — Free cash flow is negative or unavailable, meaning the DCF model could not be calculated as a fundamental valuation cross-check, leaving reliance on relative multiples.
- GROWTH SUSTAINABILITY — While revenue growth is strong at 16.2% YoY, it is decelerating from hyper-growth levels typical of earlier-stage software firms, raising the risk of further slowdown....
Gross margin stands at a very strong 75.0%, and the net margin is an impressive 28.4%, indicating highly profitable operations with significant pricing power and operational leverage. The balance sheet is notably conservative with a debt/equity ratio of 0.0x and a current ratio of 4.89x, meaning the company holds no debt and has ample short-term liquidity to cover any current obligations. Return on equity is solid at 13.4%, demonstrating efficient capital use from a profitable and debt-free equity base. Overall, Veeva’s financial health is robust and fortress-like, providing significant capacity for reinvestment in R&D and potential for future shareholder returns without any risk of balance-sheet strain.
- VALUATION — P/E of 31.4x trades at a notable 43% premium to the sector average of 22x, pricing in a high degree of future perfection. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - DCF / CASH FLOW — Free cash flow is negative or unavailable, meaning the DCF model could not be calculated as a fundamental valuation cross-check, leaving reliance on relative multiples. - GROWTH SUSTAINABILITY — While revenue growth is strong at 16.2% YoY, it is decelerating from hyper-growth levels typical of earlier-stage software firms, raising the risk of further slowdown.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives